PLRX PLIANT THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| R&D expense | $17.93M | $16.73M | $13.58M | $15.59M | $17.94M | $32.20M | $43.44M | $38.79M |
| SG&A expense | $7.81M | $7.13M | $8.19M | $7.99M | $10.33M | $13.39M | $15.50M | $14.53M |
| Operating income | -$25.74M | -$23.86M | -$21.77M | -$23.58M | -$28.27M | -$45.59M | -$58.94M | -$53.32M |
| Interest expense | $0 | $0 | $0 | $136,000 | $815,000 | $809,000 | $799,000 | $834,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$24.38M | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -$56.17M | -$49.73M |
| EBITDA | -$25.54M | -$23.66M | -$21.51M | -$23.21M | -$27.87M | -$45.19M | -$58.49M | -$52.86M |
| EPS (basic) | -0.39 | -0.36 | -0.32 | — | -0.43 | -0.71 | -0.92 | — |
| EPS (diluted) | -0.39 | -0.36 | -0.32 | — | -0.43 | -0.71 | -0.92 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 61.94M | 61.92M | 61.80M | — | 61.41M | 61.39M | 61.22M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.57M | $24.88M | $22.19M | $45.45M | $95.21M | $88.30M | $93.42M | $72.67M |
| Short-term investments | $114.52M | $133.22M | $148.70M | $145.50M | $148.06M | $176.05M | $213.71M | $284.54M |
| Current assets | $144.21M | $163.14M | $174.93M | $196.45M | $245.59M | $267.44M | $311.19M | $362.26M |
| PP&E, net | $2.18M | $2.41M | $2.66M | $2.94M | $4.34M | $4.89M | $5.24M | $5.53M |
| Total assets | $169.88M | $189.88M | $202.60M | $225.23M | $276.60M | $299.82M | $344.77M | $396.95M |
| Current liabilities | $17.92M | $16.48M | $10.36M | $16.36M | $17.62M | $20.59M | $28.20M | $33.22M |
| Long-term debt | $0 | $0 | $0 | $0 | $30.44M | $30.36M | $30.28M | $30.21M |
| Total debt | $0 | $0 | $0 | $0 | $30.44M | $30.36M | $30.28M | $30.21M |
| Total liabilities | $43.24M | $42.95M | $37.43M | $44.02M | $76.29M | $79.74M | $87.61M | $92.87M |
| Shareholders' equity | $126.63M | $146.93M | $165.17M | $181.21M | $200.31M | $220.08M | $257.16M | $304.08M |
| Net debt | -$26.57M | -$24.88M | -$22.19M | -$45.45M | -$64.78M | -$57.94M | -$63.13M | -$42.46M |
| Shares outstanding | 61.99M | 61.92M | 61.91M | 61.45M | 61.45M | 61.39M | 61.39M | 60.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.98M | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.60M | -$48.86M | -$47.66M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $112,000 | $262,000 | $209,000 |
| Free cash flow | -$16.98M | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.72M | -$49.13M | -$47.87M |
| Investing cash flow | $18.60M | $15.49M | -$4.10M | $1.77M | $27.92M | $35.49M | $69.11M | $39.13M |
| Financing cash flow | $64,000 | $0 | $74,000 | -$32.27M | $72,000 | $0 | $498,000 | $102,000 |
| Depreciation & amortization | $200,000 | $200,000 | $264,000 | $365,000 | $400,000 | $400,000 | $448,000 | $458,000 |
| Stock-based compensation | $4.15M | $4.19M | $4.25M | $4.53M | $6.42M | $6.38M | $8.91M | $8.42M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.